Biospring Management, LLCFirm match from fund name (lower confidence)
Biospring Partners CHR, LP
Open: first sale Mar 2026, per Form D (fund age approximates vintage)
- Vintage
- 2026
- Fund size
- $5M (Form D)
- Stages
- Growth
- Sectors
- Biotech
- Regions
- Not stated
01 · Thesis
Biospring partners with technology-enabled, EBITDA-positive pharma services businesses in manufacturing and clinical trial services. It backs outsourced complex biomanufacturing, clinical trial site networks, digitized clinical pathology and lab procurement platforms, and growth investments such as Serán Bioscience's CDMO expansion.Inferred from the firm's website
02 · Initial check
$167K to $313K (estimated from fund size)
Estimated from Form D
03 · Who to approach
Named on this fund's Form D
- Michelle Detwiler MD, PhD, Managing Partner
- Jeff Bullock, CFO/CCO
04 · Deals
No deals attributed to this fund yet.
05 · Evidence
Firm-wideWe partner with technology-enabled, EBITDA-positive pharma services businesses driving innovation in manufacturing and clinical trial services.
We partner with technology-enabled, EBITDA-positive pharma services businesses driving innovation in manufacturing and clinical trial services
https://biospring.com/
06 · Sources
Last verified: Oct 28, 2026